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Quality assurance (QA) for radiation therapy (RT) in clinical trials is necessary to ensure treatment is
safely and effectively administered. QA assurance requires however substantial human and ﬁnancial
resources, as it has become more comprehensive and labor intensive in recent RT trials. It is presumed
that RT deviations decrease therapeutic effectiveness of the studied regimen. This study assesses the
impact of RT protocol-deviations on patient’s outcome in prospective phase II–III RT trials. PubMed, Med-
line and Embase identiﬁed nine prospective RT trials detailing QA RT violation and patient’s outcome.
Planned QA analysis was preformed retrospectively and prospectively in eight and one studies, respec-
tively. Non-adherence to protocol-speciﬁed RT requirements in prospective trials is frequent: the
observed major deviation rates range from 11.8% to 48.0% (mean, 28.1 ± 17.9%). QA RT deviations had
a signiﬁcant impact on the primary study end-point in a majority (62.5%) of studies. The number of
patients accrued per centerwas a signiﬁcant predictive factor for RT deviations in the largest series. These
QA data stemming from prospective clinical trials show undisputedly that non adherence to protocol-
speciﬁed RT requirements is associated with reduced survival, local control and potentially increased
toxicity.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 105 (2012) 4–8Resistance to the compulsory imposition of credentialing
requirements for radiation therapy (RT) clinical trials is common
and exhibited by study chairs, participating institutions and/or
cooperative groups alike. The reasons given include, but are not
limited to, funding issues, the perceived lack of clinical beneﬁt in
QA programs/benchmarking exercises, potential loss of participat-
ing centers of those who fail the QA process, the work/time re-
quired for completing QA guidelines by an institution and the
possible delay in patient accrual. The importance of protocol-com-
pliant RT delivery in clinical trials is however of paramount impor-
tance for the design [21] and interpretation and reliability of trials,
ensuring that potentially practice-changing results are regarded as
robust, deﬁnitive and generalizable [25]. QA undisputedly de-
mands additional efforts by the participating centers and coopera-
tive groups over standard requirements imposed by clinical RT
trials, but these demands have demonstrated beneﬁts. The Radio-
logical Physics Center (RPC) observed a lower major deviation rate
in studies requiring RT credentialing [16]. Differences in delivery of
care between centers and countries can be subtle and may how-
ever induce variations that affect trial outcome.ology Department, Geneva
n.weber@hcuge.ch (D.C. We-
er CC BY-NC-ND license.It has long been presumed that deviations from study require-
ments decrease therapeutic effectiveness and/or increase compli-
cation rates. However, only recently has evidence supporting this
hypothesis been published [1,2,4,6,8,10–12,20]. This review as-
sesses the impact of RT protocol-deviations on patient’s outcome
in prospective phase II–III RT trials. The considerations on the
necessity of performing QA within clinical prospective trials will
be discussed.
Patients and methods
We searched PubMed, Medline and Embase for relevant articles
published from January 1994 to December 2012 with the terms:
‘quality assurance’, ‘protocol radiation therapy guidelines adher-
ence/compliance’, ‘radiotherapy’, ‘clinical prospective trials’ and
‘patient clinical outcome’. There were no language exclusions.
Fifty-ﬁve such studies were identiﬁed. Forty-six of the initial 55
studies were excluded because they were review papers (n = 16),
they did not report the results of a QART program (n = 13), they
were a consensus panel or international guidelines paper (n = 5),
they were QA-related treatment technique or RT audit papers
(n = 5) or they reported a QART program with no patient outcome
analysis (n = 4). One identiﬁed reference was a meta-analysis
(n = 1) and two other papers were patterns of care study (n = 1)
and QA program on chemotherapy (n = 1), respectively. Thus, nine
eligible phase II–III studies were included in this review.
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ﬁned retrospective individual case review (ICR) QA analysis. Retro-
spective QA analysis can request prospective QA submission of
study materials [1]. For this review, prospective ICR QA analysis,
or interventional QA review, was deﬁned by any review of the pa-
tient speciﬁc QA data performed before the end of the ﬁrst week of
RT. In prospective QA analysis, feed-back from the QA team was gi-
ven back to the institutions to recommend modiﬁcation of the
treatment, should the plan be non-compliant. Revised plans were
subsequently further assessed and, if necessary, additional changes
were recommended. The QA program of seven trials was retrospec-
tive [1,2,4,6,10–12]; only two papers, reporting on three trials, had
a prospective interventional QA process [8,20]. The QA process can
necessitate dummy run (DR) exercises, which is also a prospective
QA process. In this paper, we have however speciﬁcally focused on
the patient speciﬁc QA. Also complex dosimetry checks, the center
being deemed eligible to participate in the study only if passing
such a benchmarking test is performed prior to trial activation in
a given center is a prospective QA assessment, albeit not patient-
speciﬁc. Only one study ask for participating centers to be preap-
proved for intensity modulated-RT (IMRT) delivery in a Head and
Neck (H&N) study [10].Results
A substantial number of QA studies were performed for Hodg-
kin lymphoma (HL) in the 1990’s. The ﬁrst group reporting the
association between QA deviations and outcome was the South-
west Oncology Group (SWOG) in a paper published by Fabian
et al. as early as 1994 [12]. SWOG initiated a small phase III mul-
ti-institutional study assessing the efﬁcacy of low-dose RT in pre-
venting relapse in patients with advanced stage HL. The observed
rate of major and minor deviations for relapsing patients was
56.0% and 12.5% (overall, 68.5%), respectively. These data suggest
that the RT administered to patients with a HL relapse within a
clinical trial is suboptimal.
The German Hodgkin Study Group (GHSG) published the clinical
results [5], followedby a seminal paper reporting that QAdeviations
for extended-ﬁeld RT proved to be detrimental for patients with
early-stage HL in the HD4 study [6]. QA deviationswere categorized
in four tiers (Table 1). A protocol RT deviationwas observed in 37.5%
of patients (Table 2). Protocol violation was associated with signiﬁ-
cant poorer 7-year relapse-free survival (RFS; 72% vs. 84% with no
violation) for patients attaining a complete clinical response
(p = 0.004). Onmultivariate analysis, the only factor associatedwith
RFSwas a RT protocol deviation (p = 0.009). Noteworthy, the rates of
deviations varied signiﬁcantly (p = 0.005) with the number of pa-
tients accrued per center, with a cutoff of 10.
The QA retrospective analysis of the HD7 trial, assessing the
efﬁcacy of combined modality when compared to extended ﬁeld
RT only, was performed in 529 (84.4%) HL patients [11]. The QA
platform and deﬁnitions of protocol deviations were identical to
those of the HD4 trial (Table 1). Overall, protocol deviations were
observed in 63% and 68% (overall, 65.5%) of patients included in
arm A (RT alone) and B (chemo-RT). When RT deviations were lim-
ited to volume, time and delivered dose analyses, signiﬁcantly
more RT deviation was observed in the combined-modality arm,
when compared to the RT only arm (57% vs. 65%; p = 0.035). Using
the log-rank test, it is declared that freedom from treatment failure
did not differ signiﬁcantly between patients with and without pro-
tocol deviations, but no numerical ﬁgures or Kaplan Meier curves
are provided in the manuscript and this issue is not further dis-
cussed in the discussion section.
The European Organization for the Research and Treatment of
Cancer (EORTC) has also reported the QA retrospective review ofinvolved-ﬁeld RT in a phase III trial for advanced HL (EORTC
20884) [2]. Table 1 details the major protocol deviations. Overall,
63/135 (46.7%) patients hadP 1 major protocol deviations (Ta-
ble 2). Overall, 41 sites of relapse were observed in 17 patients.
Only 5/17 (29.4%) patients developed an inﬁeld relapse. No appar-
ent relationship between the presence of major deviation and in-
ﬁeld and outﬁeld failures was observed: the estimated
cumulative rate with P1 major deviation was 10% (95%CI: 4–
21%) vs. 16% (95%CI: 9–27%) in patients without major deviations
(p = 0.31). No outcome analysis has been further detailed as only
a few events have been observed and the authors considered note-
worthy a priori no reasons why there would be such a signiﬁcant
relationship.
The results of the retrospective QA analysis of a Radiation
Oncology Group (RTOG) phase II study for locally advanced pancre-
atic cancer was recently reported (RTOG 0411) [4]. Major devia-
tions are listed in Table 1. Eleven (13.4%) major deviations were
observed (Table 2). Gastro-intestinal toxicity was correlated with
major RT deviations, both during chemo-RT and maintenance che-
motherapy: the incidence of grade P3 toxicity was 45% vs. 18%
(p = 0.05) and 45% vs. 13% (p = 0.01) for patients with and without
major RT deviations, respectively.
The RTOG also published recently the results of secondary anal-
ysis of QA in a phase III trial of chemo-RT for patients with pancre-
atic cancer (RTOG 97-04) [1]. Adherence to the RT requirements
was scored as per Protocol (+PP) or less than per Protocol (PP)
(Table 1). The observed rate of deviation (PP) was 48% (Table 2).
The observed median OS for +PP and PP was 1.74 vs. 1.46 years
(p = 0.008). Deviation RT scores correlated more strongly
(p = 0.014) with survivorship than the assigned treatment arm in
multivariate analysis. Additionally, PP was associated with an in-
creased risk of local-regional failure (p = 0.016) and a trend toward
increased Grade 4/5 non-hematologic toxicity in the gemcitabine
arm (p = 0.065).
The QA-outcome results of a H&N trial (RTOG 00-22) using
IMRT have been also published [10]. All participating institutions
had to be IMRT-credentialed by the Image-Guided Therapy Center
(ITC; http://itc.wustl.edu/) using the RPC H&N phantom [19]. The
criteria for the minor and major deviations are listed in Table 1.
Forty seven (89%) and 6 (11%) cases were scored with minor and
major variations, respectively (Table 2). With a median follow-up
time of 2.8 (range, 1.4–4.8) years, 7 (10.1%) local-regional (LR) fail-
ures were observed. Two (28.6%) patients with local failures had
major deviations on PTV dose-coverage. Overall, two of the four
patients (50.0%) with PTV dose coverage deviations presented with
local failures, whereas only three out of 49 patients (6.1%) with no
PTV had LR failures. This difference was statistically signiﬁcant
(p = 0.04).
The GHSG has reported the QA review in two phase III prospec-
tive trials performed in early stage favorable (HD10) and unfavor-
able (HD11) HL [8,9]. Protocol violations are detailed in Table 1. An
acceptable volume deviation was deﬁned as a volume delineation
error in a primary non-involved region. Adherence to the RT
requirements was scored as according to protocol (+PP), acceptable
or not according to protocol (PP). The observed rate of PP-devi-
ations for treatment volumes was 36.8% and 42.5% (overall, 39.7%)
for the HD10 and HD11 study, respectively. The observed rate of -
PP-deviations for involved-ﬁeld radiation technique was 11.4% and
15.0% (overall, 13.2%) for the HD10 and HD11 study, respectively.
The Australian group reported the impact of protocol deviations
in a large phase III trial of advanced H&N cancers performed in 81
centers [20] using prospective & interventional QA. Per protocol,
QA details for each accrued patient had to be send prospectively
by the institutions to the QA team by the end of the ﬁrst week of
RT. Feedback was provided within four working days to investiga-
tors if the plan was protocol-compliant and if not, modiﬁcations
Table 1
Dosimetric deﬁnitions of major deviations for QART performed in prospective trials.
Study [ref] Years of
randomization
Major deviations (tumor) Major deviations (normal tissues)
HD 4 [5]
HD 7 [9]
1988–1993
1994–1998
 Excessive or incomplete tumor coverage by radiation
 Total dose <90% or >110% of the prescribed dose
 Dose administered too slowly
 Technical deﬁciency
ND
HD 10-HD 11 [7] 1998–2002  Deviation in the target volume delineation in a primary involved region
 90%-Isodose surface not encompassing the planning target volume
 Total delivered dose of ±10% of the prescribed randomized dose
 Overall treatment time exceeding the normal treatment time by 10%
ND
EORTC 20884 [2] 1989–2000  Omission or partial irradiation of an originally involved region
 90% isodose-surface not covering the target volume
ND
RTOG 0411 [4] 2005–2006  The inability to delineate gross tumor volume  Contoured gross tumor volume >5 cm greater
than the actual tumor size on the basis of diag-
nostic imaging
 The use of block margins >5 cm
RTOG 9704 [1] 1998–2002  Dose delivered not within ±10% of the prescribed dose ND
RTOG 0022 [8] 2001–2005  The prescription criteria for PTV66 are not met: 60 Gy isodose does not
cover P90% of PTV66. Also the 72.6 Gy isodose surface covers >25% of
PTV66
 The prescription criteria for PTV60 and PTV54 are not met: 47-Gy isodose
surface does not cover P99% of PTV54 and the 54-Gy isodose surface
does not cover P90% PTV54. The 52-Gy isodose surface does not cover
P90% of PTV60 and the 72.6-Gy isodose covers >20% PTV54 and PTV60
 60% of both parotid glands receive >30 Gy
TROG 0202 [15] 2002–2005  Dose per fraction <2 Gy
 Gross disease treated <66.6 Gy
 D10% <66.5 Gy or >75 Gy (PTV)
 Dose Spinal cord >50 Gy
 Volumes and doses to noninvolved normal tis-
sues must not be excessive
Abbreviation: ND: not deﬁned.
Table 2
Results of QART assessment with patient outcome in prospective clinical trials.
Study [ref] Type of QA Number of cases
evaluated
n (%)
Minor
deviations
n (%)
Major
deviations
n (%)
Technical
issues
with QA review
n (%)
Impact on clinical
outcome
p Value
HD 4 [5] R 368 (98.0) – 141 (37.5)* 8 (2.1) 7-year RFS with D: 72%
vs.
7-year RFS with no D: 84%
0.004
EORTC 20884 [2] R 135 (88.8) – 63 (46.7) 46 (30.3) 5-year RFS with D: 90%
vs.
5-year RFS without D: 84%
0.31
RTOG 0411 [4] R NS – 13 (13.4) NS Grade GIP 3 toxicity with D:45%
vs.
Grade GIP 3 toxicity without D:18%
0.05
RTOG 9704 [1] R 416 (92.2) – 200 (48.0)** 14/35 (40.0) mOS with D: 1.46 yo
vs.
mOS without D: 1.74 yo
0.008
RTOG 0022 [8] R 67 (97.0) 47 (89.0) 6(11.0) 14/67 (21.0) LRF with major D: 50%
vs.
LRF with no major D: 6%
0.04
TROG 0202 [15] P & R 687 (80.5) – 97 (11.8) 33/820 (4.0) OS with major D: 70%
vs.
OS without major D: 50%
<0.001
Abbreviations: R, retrospective; P, prospective; LRF, local-regional failures; D, deviations; mOS, median overall survival; RFS, relapse-free survival; GI, gastro-intestinal; NS, not
speciﬁed.
* Deviations were scored as adherence per protocol or less than per protocol (see main text for details).
** Deviations were scored as adherence to protocol-deﬁned volumes, dosimetry, treatment time and technical delivery characteristics. (see main text for details).
 Denominator is inﬂuenced by the number of patients with negative clinical outcome and/or the absence of delivered RT (see main text for details).
 QA of the TROG study was performed with a primary (interventional) prospective review and secondary review. Figures provided in Table are from the second retro-
spective review.
 Observed toxicity during chemo-radiotherapy.
 Number of evaluated cases in the interventional prospective QA program.
6 QA performed in clinical trials make a study strongerwere recommended. This primary interventional review was made
for 687/853 (81%) patients and the observed non-compliance rate
was 28.7% (197/687) and QA changes were recommended for these
cases. However, only 45% (89/197) of the non compliant plans
were modiﬁed according to the QA team recommendations. After
completion of RT, centers were required to submit retrospectively
the full QA documentation of the delivered treatment. RT devia-tions were rated into those in which the deviations were predicted
to have a major adverse effect on tumor control probability (TCP),
toxicity or both, from those that might be considered to be compat-
ible with a reasonable standard of care (Table 1). All reviews were
performed without knowledge of the randomization arm of the pa-
tient and, more importantly, before any analyses of outcome were
performed. On secondary QA assessment, the observed deviation
D.C. Weber et al. / Radiotherapy and Oncology 105 (2012) 4–8 7rate was 25.4% and approximately one out of two (47.1%) of these
deviations were predicted to have a major adverse effect on TCP.
The overall major deviation rate was 11.8% (Table 2). The devia-
tions were well balanced in both arms. Noteworthy, the observed
deviations were uncorrelated to tumor characteristics but were
signiﬁcantly associated with number of patients included by the
institution. A signiﬁcant correlation between a cutoff number of
accrued patients (n = 20) per center and the observed deviation
rate was observed. The RT-deviations for TCP for centers entering
<5, 5–9, 10–19 and P20 patients were 29.8%, 21.5%, 11.8% and
5.4%, respectively. The outcome of patients with major deviations
was suboptimal. The observed 2 year-local-regional failure and
OS were 54–50% vs. 78–70% for patients with and without major
deviations, respectively. Interestingly, the estimated local-regional
failure and OS were similar for those patients with compliant RT
plans ab initio and those with plans made compliant by the inter-
ventional QA review.Discussion
Of all studies assessing the impact of protocol delinquency on
quality of RT, ﬁve have demonstrated undisputedly that RT devia-
tions do have a detrimental impact on patient’s outcome (Table 2)
[1,4,6,10,20]. The only study that did not show an impact of RT-
quality was an unplanned retrospective QA review of patient’s RT
data with a limited number of events (17 patients receiving RT
failed) [2]. It is fair to say that QA programs are indeed important
for patients with various tumor entities entering clinical trials with
RT. Direct evidence from randomized controlled trials support the
implementation of QA in RT trials and it should be thus acknowl-
edged by the oncologic community at large that type II ASCO level
of evidence (i.e. evidence obtained from at least one well-designed
controlled clinical trial) exists supporting the concept of the RT-
QA’s impact on meaningful clinical endpoints.
The rates of RT major deviations in prospective trials are sub-
stantial, ranging from 11.0% to 48.0% (mean, 34.2 ± 20.1%; Table 2).
Noteworthy, the high rate of protocol-non compliant RT in HL is
remarkable (mean, 49.2 ± 11.7%) and should thus question any
new prospective study performed for this disease without a pro-
spective QA program. QA warrants that the uncertainty in the dose
delivered to the patient [24], associated with each step in the pro-
cess of tumor delineation, treatment planning, including data
transfer [26], and RT delivery within a prospective trial, is kept rea-
sonably low and that the RT deviations will not corrupt the overall
results of the trial [7]. The impact of RT-deviations on the overall
results of the trial could result from the imbalance of RT violations
in one arm of the study, as it was observed in the HD7 trial [11].
Additionally, poor quality RT may be selectively detrimental to
the experimental arm. In the TROG 02.02 trial, the local-regional
control was improved in the experimental arm when RT was
appropriately delivered (79% vs. 75% at 2 years), whereas it was de-
creased in the tirapazamin arm when patients received protocol
non-compliant RT (50% vs. 58%) [20]. These results strongly suggest
that suboptimally delivered RT could have masked the theoretical
and potential beneﬁt of the experimental treatment, as patients in
the tirapazamine arm received per protocol a lower dose of cis-
platin (75 mg/m2 vs. 100 mg/m2). Considering that the experimen-
tal agent has no provable single-agent antitumor activity, cisplatin
could have in essence compensated to some degree for the poor-
quality of RT in this trial.
The rate of major deviation can be substantially improved with
the implementation of prospective & interventional QA approaches
(Table 2). Notwithstanding the low deviation rates in small studies
[4,10], the QA program of the large Australian trial, randomizing
over 850 patients, provided a contemporary benchmark that futuretrials will need to exceed [20]. In this study, the low rate of devia-
tions resulted possibly from the feed-back from the QA team to the
participating investigators. Moreover, the outcome of patients with
delinquent RT planning ab initio, but subsequently modiﬁed by the
QA team, was identical to patients treated with RT with no devia-
tions. Of note, approximately 20% of patients could not be evalu-
ated in the interventional phase of the QA program. Additionally,
only 45% of the non compliant plans were modiﬁed according to
the QA team recommendations. It is the experience of the QA team
from the EORTC that prospective implementations of QA measures
are indeed problematic. In the meningioma trial (EORTC 22042-
26042), 68.6% of major deviations were observed during the pro-
spective ICRs, but only a minority of them were corrected by the
investigators and a new plan submitted to ITC (CoskumM, personal
communication). The reasons for the non-implementation of QA
recommendations ranged from frank refusal of the participating
center to modify the RT plan to the noncommittal role of the QA
team from a supra-national organization that cannot require com-
pulsory treatment modiﬁcations of a patient treated in a partici-
pating institution. The latter issue has been acknowledged during
an EORTC QA strategic meeting in December 2011, during which
the decision of deﬁning pre-agreed algorithm of actions for late/
non-data submission and protocol-delinquent plans for the QA
team has been agreed upon.
Few studies have speciﬁcally assessed the impact of protocol-
delinquent RT on patient’s outcome. Even fewer have addressed
the potential predictors of RT deviations. When analyzed, the num-
ber of accrued patients per center has been signiﬁcantly associated
with the quality of the delivered RT within a prospective protocol,
with a cutoff ranging from 10 to 20. Given the costs for cooperative
groups for institutional activation and the potential detrimental ef-
fect on RT of the center’s accruing capacity, it is reasonable to as-
sume that any institution that cannot randomize 10–20 patients
in a given trial should not be authorized to treat patients in co-
operative group’s studies.
Since 2000’s, the study protocol delinquency’s deﬁnition has
incorporated metrics for normal tissue complications (Table 1).
This trend is particularly relevant for dose-escalation RT studies
and QA parameters for toxicity should be incorporated in future
trials. The EORTC has therefore developed a template trial protocol
with standard RT and QART chapters. These templates ensure that
the QA wording is generic and will avoid thus misunderstanding of
treatment guidelines that would lead consequentially to poor pro-
tocol compliance. The ICR analysis of the phase III low grade glioma
study has shown that 1 patient out of 4 had no delineation of OAR
and, more importantly, that only 30% of target volumes had proto-
col-compliant target volumes [14]. To unambiguously describe
within the trial protocol target volumes with their respective pre-
scribed dose level and margins and to describe the organs at risk
and margins, the EORTC has adopted the ICRU 62 formalism [17]
and the new uniform naming convention [22], respectively. One
of the most important opportunities facing the various cooperative
groups and QA centers is the potential for harmonization of inter-
national QA requirements and RT credentialing processes in clini-
cal trials. More speciﬁcally, the large variation in deﬁnitions of
major andminor protocol deviations should be addressed (Table 1).
This task is currently conducted by the Harmonization Group
(http://www.atomic.gr/WQH/) whose main objective is to harmo-
nize and improve the QA of RT delivered worldwide.
QA programs for clinical trials may also improve the treatment
delivery accuracy of patients not included in prospective studies by
implementing treatment protocols and increasing the physic sup-
port [3]. The TROG reported the set-up accuracy of institutions in
a benchmarking exercise for the dose escalation ‘RADAR’ study
for intermediate and high-risk prostate cancer patients (TROG
03.04) [15]. Prior to this credentialing program, only a minority
8 QA performed in clinical trials make a study stronger(2/24; 8.3%) of centers did perform routinely set-up accuracy anal-
yses for their prostate cancer patients. A booklet, set-up manager
software, educational lectures and patient position protocols were
provided to institutions to help to improve their treatment accu-
racy. Centers were advised to contact the QA committee for advice
on methods to improve their positioning data in order to achieve
the trial recommendations. The majority (13/20; 65.0%) did indeed
report a change in clinical practice resulting from the clinical trial
QA requirements. This study shows that a QA clinical trial-orien-
tated program has resulted in development of treatment guidelines
and changes in institutional practices. These data are in line with
other studies that have reported that the beneﬁts of a speciﬁed
QA trial program extend beyond improving the quality of RT deliv-
ered to accrued patients in a trial [18,23].
Finally, the logistical issues involved in prospective and inter-
ventional QA within a clinical trial can be substantial and challeng-
ing. Overall, between 2% and 40% of the patient’s treatment plans
included in prospective trials cannot be assessed by the QA teams
(Table 2). Although digital central QA review using a web-based
platform facilitates and speeds up the overall QA process [13],
data-format, newer treatment delivery systems and multimodality
imaging pose new challenges for cooperative groups and QA
centers.
In summary, these QA data stemming from prospective clinical
trials show undisputedly that non adherence to protocol-speciﬁed
RT requirements are frequent. Moreover, failure to adhere to proto-
col RT guidelines is associated with reduced survival, local control
and potentially increased toxicity. Non-protocol compliant RT in
clinical trials may waste time, effort and money and could more
importantly harm patients.
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